Difference between revisions of "Team:CGU Taiwan/Background"

 
(33 intermediate revisions by 3 users not shown)
Line 95: Line 95:
 
}
 
}
 
.left {
 
.left {
−
   position: fixed;
+
  padding: 10px;
 +
  height:200px;
 +
  border-color:#140731;
 +
  border-radius:8px;
 +
  border-width:2px;
 +
  border-style:solid;
 +
   position: absolute;
 
   left: 25px;
 
   left: 25px;
 
   top: 230px;
 
   top: 230px;
Line 103: Line 109:
 
   z-index:+1;
 
   z-index:+1;
 
}
 
}
 +
 
.left-tab {
 
.left-tab {
 
   background-color: rgba(250, 250, 250, 0.1);
 
   background-color: rgba(250, 250, 250, 0.1);
Line 126: Line 133:
 
   border-radius: 4px;
 
   border-radius: 4px;
 
}
 
}
 +
.fixed2 {
 +
  position: fixed;
 +
  top: 68px;
 +
}
 +
 
.button {
 
.button {
 
   background-color: rgba(250, 250, 250, 0.1);
 
   background-color: rgba(250, 250, 250, 0.1);
Line 254: Line 266:
 
   padding-left:3%;
 
   padding-left:3%;
 
   background-size:2.5%;
 
   background-size:2.5%;
 +
}
 +
 +
.end2 {
 +
  background-color:#0D014D;
 +
  position: absolute;
 +
  width: 100%;
 +
  height: 200%;
 +
  font-family: Corbel;
 +
  z-index:+1;
 +
}
 +
.sitemap {
 +
  background-color:#0D014D;
 +
  position: absolute;
 +
  width: 20%;
 +
  height: 40%;
 +
  font-family: Corbel;
 +
}
 +
.list1 li {
 +
  list-style:none;
 +
  background-image:url(https://static.igem.org/mediawiki/2016/5/58/CGU_Taiwan--sitemap.jpg);
 +
  background-repeat:no-repeat;
 +
  background-position:10px;
 +
  background-size:9%;
 +
    margin-bottom:-20%;
 +
}
 +
.list2 li {
 +
  list-style:none;
 +
  background-image:url(https://static.igem.org/mediawiki/2016/2/2f/CGU_Taiwan--sitemap2.jpg);
 +
  background-repeat:no-repeat;
 +
  background-position:6px;
 +
  background-size:7%;
 +
  margin-bottom:-10%;
 +
}
 +
.list3 li {
 +
  list-style:none;
 +
  background-image:url(https://static.igem.org/mediawiki/2016/3/31/CGU_Taiwan--sitemap3.jpg);
 +
  background-repeat:no-repeat;
 +
  background-position:5%;
 +
  background-size:2%;
 +
  margin-bottom:-10%;
 
}
 
}
 
</style>
 
</style>
Line 268: Line 320:
 
     } else {
 
     } else {
 
         $('.header-subnav').removeClass('fixed1');
 
         $('.header-subnav').removeClass('fixed1');
 +
    }
 +
});
 +
 +
var num = 132; //number of pixels before modifying styles
 +
$(window).bind('scroll', function () {
 +
    if ($(window).scrollTop() > num) {
 +
        $('.left').addClass('fixed2');
 +
    } else {
 +
        $('.left').removeClass('fixed2');
 
     }
 
     }
 
});
 
});
Line 306: Line 367:
  
 
<body>
 
<body>
 +
<a name='anchor1'></a>
 
<div class="top">
 
<div class="top">
 
<img style="margin-top:-2%;width:100%;height:140%;position:absolute;" src="https://static.igem.org/mediawiki/2016/0/0b/CGU_Taiwan--top.jpg">
 
<img style="margin-top:-2%;width:100%;height:140%;position:absolute;" src="https://static.igem.org/mediawiki/2016/0/0b/CGU_Taiwan--top.jpg">
Line 326: Line 388:
 
</header>
 
</header>
  
−
<div class="left" style="height:40%; border-color:#140731; border-radius:8px;border-width:2px;border-style:solid;">
+
<div class="left">
−
<a href="#anchor0"><section class="left-tab" style="position:fixed;top:240px;left:35px;" id="myP" onmousedown="mouseDown()" onmouseup="mouseUp()">TOP</section>
+
<a href="#anchor1"><section class="left-tab" style="top:240px;" id="myP" onmousedown="mouseDown()" onmouseup="mouseUp()"><b>TOP</b></section></a>
−
<a href="#anchor1"><section class="left-tab" style="position:fixed;top:275px;left:50px;">Overview</section>
+
<a href="https://2016.igem.org/Team:CGU_Taiwan/Description"><section class="left-tab" style="top:275px;left:50px;">Overview</section></a>
−
<a href="https://2016.igem.org/Team:CGU_Taiwan/Design"><section class="left-tab" style="position:fixed;top:310px;left:50px;">Design</section>
+
<a href="https://2016.igem.org/Team:CGU_Taiwan/Design"><section class="left-tab" style="top:310px;left:50px;">Design</section></a>
−
<a href="https://2016.igem.org/Team:CGU_Taiwan/Background"><section class="left-tab" style="position:fixed;top:345px;left:50px;">Background</section>
+
<a href="https://2016.igem.org/Team:CGU_Taiwan/Background"><section class="left-tab" style="top:345px;left:50px;">Background</section></a>
−
<a href="https://2016.igem.org/Team:CGU_Taiwan/Results"><section class="left-tab" style="position:fixed;top:380px;left:50px;">Results</section>
+
<a href="https://2016.igem.org/Team:CGU_Taiwan/Results"><section class="left-tab" style="top:380px;left:50px;">Results</section></a>
−
<a href="https://2016.igem.org/Team:CGU_Taiwan/Proof"><section class="left-tab" style="position:fixed;top:415px;left:50px;">Proof concept</section>
+
<a href="https://2016.igem.org/Team:CGU_Taiwan/Proof"><section class="left-tab" style="top:415px;left:50px;">Proof</section></a>
−
<a href="https://2016.igem.org/Team:CGU_Taiwan/Notebook"><section class="left-tab" style="position:fixed;top:450px;left:50px;">Notebook</section>
+
<a href="https://2016.igem.org/Team:CGU_Taiwan/Notebook"><section class="left-tab" style="top:450px;left:50px;">Notebook</section></a>
 
</div>
 
</div>
 +
  
 
<br><br><br>
 
<br><br><br>
Line 342: Line 405:
 
</div>
 
</div>
 
<br><br>
 
<br><br>
−
<div style="border:2px #0D014D solid;border-radius:6px;padding:4px;margin-left:24%;margin-right:30%;">
+
<div style="border:2px #0D014D solid;border-radius:6px;padding:4px;margin-left:24%;margin-right:20%;">
 
<br>
 
<br>
−
<a href="#anchor1" style="font-size:20px;text-decoration:none;color:#0D014D;margin-left:15%;">1. Leishmania</a><br>
+
<div style="font-size:20px;text-decoration:none;color:#0D014D;margin-left:15%;">1. Leishmania<br></div>
−
<a href="#anchor2" style="font-size:20px;text-decoration:none;color:#0D014D;margin-left:15%;">2. Leishmania as a model organism</a><br>
+
<div style="font-size:20px;text-decoration:none;color:#0D014D;margin-left:15%;">2. Leishmania as a model organism<br></div>
−
<a href="#anchor3" style="font-size:20px;text-decoration:none;color:#0D014D;margin-left:15%;">3. Basic Information of Adjuvant</a><br>
+
<div style="font-size:20px;text-decoration:none;color:#0D014D;margin-left:15%;">3. Basic Information of Adjuvant<br></div>
 
<br>
 
<br>
 
</div>
 
</div>
 
<br><br><br>
 
<br><br><br>
−
<img src="https://static.igem.org/mediawiki/2016/thumb/9/91/CGU_Taiwan--background1.jpg/576px-CGU_Taiwan--background1.jpg.png" style="float:right;width:34%;height:525%;margin:20px;">
+
<img src="https://static.igem.org/mediawiki/2016/thumb/9/91/CGU_Taiwan--background1.jpg/576px-CGU_Taiwan--background1.jpg.png" style="float:right;width:34%;height:200%;margin:20px;">
 
<br>
 
<br>
 
<a name='anchor1'></a>
 
<a name='anchor1'></a>
Line 357: Line 420:
 
<br><br>
 
<br><br>
 
<div style="color:black;font-size:18px;margin-left:22%;margin-right:4%;text-align:justify;text-decoration:none;">
 
<div style="color:black;font-size:18px;margin-left:22%;margin-right:4%;text-align:justify;text-decoration:none;">
−
Leishmania is a genus of trypanosomes protozoa that are responsible for leishmaniasis, a blood-borne disease spread by blood-sucking sandflies. Leishmania multiply and develop extracellularly as promastigotes in the digestive tract of the sandflies. When the female fly takes blood meals, the promastigotes are delivered into the skin of the mammalian host. They will directly infect macrophages, where they differentiate into amastigotes and multiply intracellularly as such.
+
Leishmania is a genus of trypanosomes protozoa that are responsible for leishmaniasis, a blood-borne disease spread by blood-sucking sandflies. Leishmania multiply and develop extracellularly as promastigotes in the digestive tract of the sandflies. When the female fly takes blood meals, the promastigotes are delivered into the skin of the mammalian host. They will directly infect macrophages, where they differentiate into amastigotes and multiply intracellularly as such.<sup>[1]</sup>
 
</div>
 
</div>
−
<br><br><br><br><br><br><br>
+
<br><br><br><br><br><br><br><br><br><br><br><br>
 
<a name='anchor2'></a>
 
<a name='anchor2'></a>
 
<br>
 
<br>
 
<b style="color:#0D014D;font-size:28px;margin-left:22%;">Leishmania as a model organism</b>
 
<b style="color:#0D014D;font-size:28px;margin-left:22%;">Leishmania as a model organism</b>
−
<img src="https://static.igem.org/mediawiki/2016/d/df/CGU_Taiwan--background2.jpg" style="float:right;width:40%;height:480%;margin-top:-5%;">
+
<img src="https://static.igem.org/mediawiki/2016/d/df/CGU_Taiwan--background2.jpg" style="float:right;width:40%;height:180%;margin-top:-5%;">
 
<br><br>
 
<br><br>
 
<div style="color:black;font-size:18px;margin-left:22%;margin-right:4%;text-align:justify;text-decoration:none;">
 
<div style="color:black;font-size:18px;margin-left:22%;margin-right:4%;text-align:justify;text-decoration:none;">
Line 373: Line 436:
 
</div>
 
</div>
 
<br><br>
 
<br><br>
−
<img src="https://static.igem.org/mediawiki/2016/f/f4/CGU_Taiwan--background3.jpg" style="float:left;width:37%;height:500%;margin-left:22%;margin-right:3%;">
+
<img src="https://static.igem.org/mediawiki/2016/f/f4/CGU_Taiwan--background3.jpg" style="float:left;width:37%;height:200%;margin-left:22%;margin-right:3%;">
 
<br><br>
 
<br><br>
 
<div style="color:black;font-size:18px;margin-left:22%;margin-right:4%;text-align:justify;text-decoration:none;">
 
<div style="color:black;font-size:18px;margin-left:22%;margin-right:4%;text-align:justify;text-decoration:none;">
−
First, it can be specifically recognized by antigen-presenting cells for delivery with higher efficiency. Second, the photo-inactivation of Leishmania provides the safety of this platform for vaccine delivery. These two advantages suggest that photo-inactivated Leishmania can be a novel system of immunologic adjuvant, leading to the next generation of vaccination.<br><br>Professor Kwang Poo Chang established this double-photo inactivation system of Leishmania and validated its role in modulating immune response.
+
First, it can be specifically recognized by antigen-presenting cells for delivery with higher efficiency. Second, the photo-inactivation of Leishmania provides the safety of this platform for vaccine delivery. These two advantages suggest that photo-inactivated Leishmania can be a novel system of immunologic adjuvant, leading to the next generation of vaccination.<br><br>Professor Kwang Poo Chang established this double-photo inactivation system of Leishmania and validated its role in modulating immune response.<sup>[2]</sup>
 
</div>
 
</div>
 
<br><br><br><br><br>
 
<br><br><br><br><br>
Line 384: Line 447:
 
<br><br>
 
<br><br>
 
<div style="color:black;font-size:18px;margin-left:22%;margin-right:4%;text-align:justify;text-decoration:none;">
 
<div style="color:black;font-size:18px;margin-left:22%;margin-right:4%;text-align:justify;text-decoration:none;">
−
Vaccine provides active adaptive immunity to a particular pathogen. Commonly used vaccines can be divided into four categories: attenuated, inactivated, sub-unit, and recombinant vaccines. Since inactivated, sub-unit and recombinant vaccines are often poorly immunogenic, additional components, aka adjuvant, are required to help stimulating antibody production and effector T cell functions. Immunologic adjuvants are compounds that can strongly activate both innate and adaptive immune system.
+
Vaccine provides active adaptive immunity to a particular pathogen. Commonly used vaccines can be divided into four categories: attenuated, inactivated, sub-unit, and recombinant vaccines. Since inactivated, sub-unit and recombinant vaccines are often poorly immunogenic, additional components, aka adjuvant, are required to help stimulating antibody production and effector T cell functions. Immunologic adjuvants are compounds that can strongly activate both innate and adaptive immune system.<sup>[3]</sup>
 
<br><br>
 
<br><br>
 
Adjuvants can be used for several purposes:
 
Adjuvants can be used for several purposes:
Line 391: Line 454:
 
<li>To enhance the immune responses of purified or recombinant antigens.</li>
 
<li>To enhance the immune responses of purified or recombinant antigens.</li>
 
<li>To reduce the amount of antigen or the number of immunizations needed for inducing protective immunity.</li>
 
<li>To reduce the amount of antigen or the number of immunizations needed for inducing protective immunity.</li>
−
<li>To improve the efficacy of vaccines for people with weaker immune responses, such as newborns, elders.</li></ol>
+
<li>To improve the efficacy of vaccines for people with weaker immune responses, such as newborns, elders<sup>[4]</sup>.</li></ol>
 
</div>
 
</div>
 
<br><br>
 
<br><br>
 
<div style="color:black;font-size:18px;margin-left:22%;margin-right:4%;text-align:justify;text-decoration:none;">
 
<div style="color:black;font-size:18px;margin-left:22%;margin-right:4%;text-align:justify;text-decoration:none;">
−
Adjuvants mediate their effects mainly through innate mechanism. When pathogens invade the human body, the innate immune system is first activated and responsible for the initial attack against the pathogens. Dendritic cells then act as antigen-presenting cells and migrate from infected tissue to regional lymph nodes to present the antigens to T cells.
+
Adjuvants mediate their effects mainly through innate mechanism. When pathogens invade the human body, the innate immune system is first activated and responsible for the initial attack against the pathogens. Dendritic cells then act as antigen-presenting cells and migrate from infected tissue to regional lymph nodes to present the antigens to T cells<sup>[5]</sup>. Adjuvants enhance the innate immune responses and create a bridge between innate and adaptive immunity to induce effective immunity.
−
<br>
+
−
Adjuvants enhance the innate immune responses and create a bridge between innate and adaptive immunity to induce effective immunity.
+
 
<br><br>
 
<br><br>
−
The comparison of most commonly used commercial adjuvants Alum and MF59:
+
The comparison of most commonly used commercial adjuvants Alum and MF59<sup>[4],[6]</sup>:
 
</div>
 
</div>
 
<br><br>
 
<br><br>
−
<img src="https://static.igem.org/mediawiki/2016/b/b6/CGU_Taiwan--background4.jpg" style="float:right;width:40%;height:550%;margin-top:0%;margin-left:5%;"></img>
+
<img src="https://static.igem.org/mediawiki/2016/5/57/CGU_Taiwan_ajuvant_comparison2.png" style="width:70%;height:160%;margin-top:0%;margin-left:22%;"></img>
−
<br><br>
+
<br><br><br>
 
<div style="color:black;font-size:18px;margin-left:22%;margin-right:4%;text-align:justify;text-decoration:none;">
 
<div style="color:black;font-size:18px;margin-left:22%;margin-right:4%;text-align:justify;text-decoration:none;">
 
Alum is still the main adjuvant approved for human use worldwide. MF59 was widely used in influenza vaccines since the outbreak of the H1N1. No severe side effects were reported for MF59. However, MF59 is still under inspection due to lack of long-term analysis. Despite the success of current adjuvants, there is still a need for further improvement. Specifically, the challenge is to make adjuvant stimulating stronger T cell response and antibody production for protective immunity.
 
Alum is still the main adjuvant approved for human use worldwide. MF59 was widely used in influenza vaccines since the outbreak of the H1N1. No severe side effects were reported for MF59. However, MF59 is still under inspection due to lack of long-term analysis. Despite the success of current adjuvants, there is still a need for further improvement. Specifically, the challenge is to make adjuvant stimulating stronger T cell response and antibody production for protective immunity.
−
<br><br><br>
+
<br><br><br><br><br><br>
 +
<div style="font-size:12px;">
 +
References:<br>
 +
1. Chang, K.P., Leishmaniases, in eLS. 2001, John Wiley & Sons, Ltd.<br>
 +
2. Chang, K.P., B.K. Kolli, and G. New Light, New "light" for one-world approach toward safe and effective control of animal diseases and insect vectors from leishmaniac perspectives. Parasit Vectors, 2016. 9(1): p. 396.<br>
 +
3. Reed, S.G., M.T. Orr, and C.B. Fox, Key roles of adjuvants in modern vaccines. Nat Med, 2013. 19(12): p. 1597-608.<br>
 +
4. Petrovsky, N. and J.C. Aguilar, Vaccine adjuvants: Current state and future trends. Immunol Cell Biol, 2004. 82(5): p. 488-496.<br>
 +
5. Coffman, R.L., A. Sher, and R.A. Seder, Vaccine Adjuvants: Putting Innate Immunity to Work. Immunity, 2010. 33(4): p. 492-503.<br>
 +
6. O'Hagan, D.T., et al., The history of MF59((R)) adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines, 2013. 12(1): p. 13-30.<br>
 +
</div>
 +
 
 
</div>
 
</div>
 
<br><br><br>
 
<br><br><br>
 
</div>
 
</div>
  
 +
<div class="end2" style="margin-top:260%;">
 +
<br>
 +
<ul class="list3" class="margin-left:1%;margin-top:2%;">
 +
<li><a href="#anchor1"><b style="color:white;font-size:28px;margin-left:7%;">TOP</a></li>
 +
</ul>
 +
<br>
 +
<div class="sitemap" style="margin-left:5%;">
 +
<br>
 +
<b style="color:white;font-size:28px;margin-top:5%;margin-left:4%;text-decoration:none;">SITE MAP</b><br>
 +
<br><br>
 +
<img style="background-color:#0D014D;margin-left:20%;border-radius:50%;border:6px solid white;padding:5px;width:40%;height:70%;position:absolute;margin-left:2%;" src="https://static.igem.org/mediawiki/2016/0/03/CGU_Taiwan--leishmania3.jpg">
 +
</div>
 +
<br>
 +
 +
<div class="sitemap" style="margin-left:22%;margin-top:-1%;">
 +
<ul class="list1" class="margin-left:5%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan"><b style="color:white;font-size:18px;margin-left:20%;">HOME</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Achievements"><b style="color:white;font-size:18px;margin-left:20%;">ACHIEVEMENTS</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Interlab"><b style="color:white;font-size:18px;margin-left:20%;">INTERLAB</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Safety"><b style="color:white;font-size:18px;margin-left:20%;">SAFETY</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Parts"><b style="color:white;font-size:18px;margin-left:20%;">PARTS</li></a>
 +
</ul>
 +
</div>
 +
 +
<div class="sitemap" style="margin-left:40%;margin-top:-2%;">
 +
<ul class="list1" class="margin-left:5%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Description"><b style="color:white;font-size:18px;margin-left:20%;">PROJECT</li></a>
 +
<br><br>
 +
<ul class="list2" class="margin-left:6%;margin-top:50%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Design"><b style="color:white;font-size:17px;margin-left:10%;">Design</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Background"><b style="color:white;font-size:17px;margin-left:10%;">Background</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Results"><b style="color:white;font-size:17px;margin-left:10%;">Results</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Proof"><b style="color:white;font-size:17px;margin-left:10%;">Proof</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Notebook"><b style="color:white;font-size:17px;margin-left:10%;">Notebook</li></a>
 +
<br><br>
 +
</ul>
 +
</ul>
 +
</div>
 +
 +
<div class="sitemap" style="margin-left:55%;margin-top:-3.5%;">
 +
<ul class="list1" class="margin-left:5%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices"><b style="color:white;font-size:18px;margin-left:20%;">HUMAN PRACTICES</li></a>
 +
<br><br>
 +
<ul class="list2" class="margin-left:6%;margin-top:50%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Survey"><b style="color:white;font-size:17px;margin-left:10%;">Survey</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Education"><b style="color:white;font-size:17px;margin-left:10%;">Education</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Communication"><b style="color:white;font-size:17px;margin-left:10%;">Communication</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Entrepreneurship"><b style="color:white;font-size:17px;margin-left:10%;">Entrepreneurship</li></a>
 +
</ul>
 +
</ul>
 +
</div>
 +
 +
<div class="sitemap" style="margin-left:75%;margin-top:-3.5%;">
 +
<ul class="list1" class="margin-left:5%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Software"><b style="color:white;font-size:18px;margin-left:20%;">MODELING</li></a>
 +
<br><br>
 +
<ul class="list2" class="margin-left:6%;">
 +
<li><a href="http://163.25.92.36/igemcgu/igemwebhome.htm"><b style="color:white;font-size:17px;margin-left:10%;">McHug</li></a>
 +
</ul>
 +
</ul>
 +
<ul class="list1" class="margin-left:1%;margin-top:-10%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Team"><b style="color:white;font-size:18px;margin-left:20%;">OUR TEAM</li></a>
 +
<br><br>
 +
<ul class="list2" class="margin-left:6%;margin-top:-5%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Collaborations"><b style="color:white;font-size:17px;margin-left:10%;">Collaborations</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Attributions"><b style="color:white;font-size:17px;margin-left:10%;">Attributions</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Team#anchor2"><b style="color:white;font-size:17px;margin-left:10%;">Sponsors</li></a>
 +
</ul>
 +
</ul>
 +
</div>
 +
</div>
  
  
 
</body>
 
</body>
 
</html>
 
</html>

Latest revision as of 05:40, 2 December 2016

TOP
Overview
Design
Background
Results
Proof
Notebook



Background



1. Leishmania
2. Leishmania as a model organism
3. Basic Information of Adjuvant






Leishmania

Leishmania is a genus of trypanosomes protozoa that are responsible for leishmaniasis, a blood-borne disease spread by blood-sucking sandflies. Leishmania multiply and develop extracellularly as promastigotes in the digestive tract of the sandflies. When the female fly takes blood meals, the promastigotes are delivered into the skin of the mammalian host. They will directly infect macrophages, where they differentiate into amastigotes and multiply intracellularly as such.[1]













Leishmania as a model organism

Leishmania are aerobic organisms that rely on oxidative phosphorylation, but are defective in the synthesis of heme which is required for electron transport respiratory complexes. The genetic deficiency of heme biosynthesis in Leishmania makes it possible to produce transgenic DT mutants, which are inducible with delta-aminolevulinate (ALA) for accumulation of uroporphyrin I (URO) as a photosensitizer (PS).


Photosensitizers like uroporphyrin and aluminum phthalocyanine (PC) can be excited when illuminated at specific wavelengths and produce singlet oxygen and reactive oxygen species (ROS) to kill these parasitic protozoa (Oxidative inactivation).We adapted a combinational approach by loading the Leishmania DT mutants both endogenously with URO via the use of ALA and exogenously with PC. After URO and PC are illuminated by specific wavelength of light, double inactivation will kill Leishmania with proven effectiveness. Therefore, photo-inactivated Leishmania may be used as a carrier for delivery of antigen proteins to the antigen-presenting cells and induce humoral and cell-mediated immunity. This photodynamic Leishmania system provides us two major advantages to produce immunologic adjuvant.




First, it can be specifically recognized by antigen-presenting cells for delivery with higher efficiency. Second, the photo-inactivation of Leishmania provides the safety of this platform for vaccine delivery. These two advantages suggest that photo-inactivated Leishmania can be a novel system of immunologic adjuvant, leading to the next generation of vaccination.

Professor Kwang Poo Chang established this double-photo inactivation system of Leishmania and validated its role in modulating immune response.[2]






Basic Information of Adjuvant

Vaccine provides active adaptive immunity to a particular pathogen. Commonly used vaccines can be divided into four categories: attenuated, inactivated, sub-unit, and recombinant vaccines. Since inactivated, sub-unit and recombinant vaccines are often poorly immunogenic, additional components, aka adjuvant, are required to help stimulating antibody production and effector T cell functions. Immunologic adjuvants are compounds that can strongly activate both innate and adaptive immune system.[3]

Adjuvants can be used for several purposes:
  1. To enhance the immune responses of purified or recombinant antigens.
  2. To reduce the amount of antigen or the number of immunizations needed for inducing protective immunity.
  3. To improve the efficacy of vaccines for people with weaker immune responses, such as newborns, elders[4].


Adjuvants mediate their effects mainly through innate mechanism. When pathogens invade the human body, the innate immune system is first activated and responsible for the initial attack against the pathogens. Dendritic cells then act as antigen-presenting cells and migrate from infected tissue to regional lymph nodes to present the antigens to T cells[5]. Adjuvants enhance the innate immune responses and create a bridge between innate and adaptive immunity to induce effective immunity.

The comparison of most commonly used commercial adjuvants Alum and MF59[4],[6]:





Alum is still the main adjuvant approved for human use worldwide. MF59 was widely used in influenza vaccines since the outbreak of the H1N1. No severe side effects were reported for MF59. However, MF59 is still under inspection due to lack of long-term analysis. Despite the success of current adjuvants, there is still a need for further improvement. Specifically, the challenge is to make adjuvant stimulating stronger T cell response and antibody production for protective immunity.





References:
1. Chang, K.P., Leishmaniases, in eLS. 2001, John Wiley & Sons, Ltd.
2. Chang, K.P., B.K. Kolli, and G. New Light, New "light" for one-world approach toward safe and effective control of animal diseases and insect vectors from leishmaniac perspectives. Parasit Vectors, 2016. 9(1): p. 396.
3. Reed, S.G., M.T. Orr, and C.B. Fox, Key roles of adjuvants in modern vaccines. Nat Med, 2013. 19(12): p. 1597-608.
4. Petrovsky, N. and J.C. Aguilar, Vaccine adjuvants: Current state and future trends. Immunol Cell Biol, 2004. 82(5): p. 488-496.
5. Coffman, R.L., A. Sher, and R.A. Seder, Vaccine Adjuvants: Putting Innate Immunity to Work. Immunity, 2010. 33(4): p. 492-503.
6. O'Hagan, D.T., et al., The history of MF59((R)) adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines, 2013. 12(1): p. 13-30.






SITE MAP